A phase 1, dose-escalation study of gilteritinib combined with chemotherapy in patients aged 6 months to <21 years with FLT3 internal tandem duplication-positive relapsed or refractory AML

Category Primary study
JournalBlood
Year 2021
This article has no abstract
Epistemonikos ID: edbe74420686949a4f52c9092ce173434cfccda5
First added on: Feb 13, 2025